| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 84 | 12.8x | 17.8x | Top tier | |
Growth | 41 | 0.5% | 7.1% | Around median | |
Quality | 71 | 11.0% | 4.5% | Top tier | |
Safety | 71 | 0.9x | 2.6x | Top tier | |
Capital Return | 83 | — | 2.12% | Top tier | |
Momentum | 94 | 52.6% | 2.9% | Top tier | |
Sentiment | 61 | 5 | 3 | Around median |
Estimates — analyst targets and a simplified DCF, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Pediatrix Medical Group provides specialized medical services for women and children through an extensive network that includes more than 360 neonatal intensive care units in 32 states, along with more than 170 maternal-fetal medicine specialists and relationships with more than 400 hospitals. Revenue generation depends on hospital-based patient services, particularly neonatology and maternal-fetal medicine, and returns are affected by patient volumes, case complexity, payer mix, contract terms, and the efficiency of revenue cycle management and cash collections. The company is also expanding its hybrid care model, which combines in-person services and telemedicine in areas including maternal-fetal medicine, neonatology, neurology, infectious diseases, and retinopathy.
In fiscal year 2026 quarter 2, revenue was $487.8 million, gross profit was $132.5 million, net income was $39.8 million, and earnings per share were $0.49; this equates to a calculated gross margin of approximately 27.2% and a net income margin of approximately 8.2%. Consolidated revenue increased 4%, supported by non-same-unit activity, particularly completed acquisitions, and same-unit growth of 2%, while same-unit pricing increased 4% despite a 2% decline in same-unit patient service volumes. Adjusted earnings before interest, taxes, depreciation, and amortization were $76 million, with strong cash collections, improved payer mix, and greater neonatal case complexity offsetting the volume decline.
Automated analysis for informational purposes only — not investment advice.
The average analyst price target is $26.6, within a relatively narrow range of $24 to $28, and the average is below the 52-week range high of $27.94 and above its low of $15.70. The Neutral consensus reflects a balance between improved profitability, collections, and share repurchases on the one hand, and the risks of declining volumes and the fading impact of strong collections during the second half of fiscal year 2026 on the other; the data do not include a usable earnings multiple.
Figures in the text are as of 2026-09-01; the live price is shown at the top of the page.
Consolidated revenue increased 4% in fiscal year 2026 quarter 2, supported by non-same-unit activity, particularly completed acquisitions, and same-unit growth of 2%. Same-unit pricing increased 4% due to cash collections, payer mix, and greater case complexity, which together accounted for approximately 95% of pricing growth. These factors offset a 2% decline in same-unit patient service volumes and a 3% decrease in neonatal intensive care unit days.
Management reaffirmed during the August 4, 2026 call the fiscal year 2026 adjusted earnings before interest, taxes, depreciation, and amortization range of $280 million to $300 million. This measure was $76 million in fiscal year 2026 quarter 2. Management expects second-half adjusted earnings to be distributed approximately evenly between the third and fourth quarters, with general and administrative expenses trending toward the upper end of the $230 million to $240 million range for fiscal year 2026.
Same-unit patient service volumes declined 2% during fiscal year 2026 quarter 2, with the weakness concentrated in hospital-based services, particularly neonatology. Neonatal intensive care unit days also fell 3%, despite greater case complexity. Management expects to end fiscal year 2026 with volumes that are flat or slightly lower and acknowledged that it does not know whether the decline will become a sustained trend.
Cash was $289 million in fiscal year 2026 quarter 2, compared with total debt of $584 million and net debt of slightly more than $295 million. Leverage was slightly above one times based on the midpoint of the fiscal year 2026 adjusted earnings outlook range. The company also generated $126 million in operating cash flow during the quarter, down from $138 million in the corresponding period.
Pediatrix is building a national remote care function that complements in-person visits rather than replacing them. The initiative is based on more than 170 maternal-fetal medicine specialists and more than 360 neonatal intensive care units in 32 states. The areas of expansion mentioned during the August 4, 2026 call include maternal-fetal medicine, neonatology, neurology, infectious diseases, and retinopathy, but the data do not provide a separate financial target for this initiative.
The analyst consensus on MD stock is Neutral, with an average price target of $26.6. The lowest target is $24 and the highest target is $28, compared with a 52-week range of $15.70 to $27.94. The average target is below the 52-week range high, which is consistent with a balanced view of improved fiscal year 2026 quarter 2 results and the risks related to volumes and the later fading of the collections benefit.
